Coriolis Pharma is the premier partner for drug product development, analytical services, and manufacturing services across a vast array of biological therapeutic modalities. We provide our services under both R&D and GMP conditions, always bearing in mind the optimal solution for you. With a focus on liquid and lyophilized drug products, our expert scientists design and execute our platform and custom services to accelerate and derisk your program right from the start and throughout the entire product lifecycle.
Latest News
NEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly availableNEW PUBLICATION: Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical FormulationsNEW PUBLICATION: Optimization and transfer of robust primary drying protocols for biopharmaceuticals through lyophilization process modelingThree new publications by Coriolis scientists now publicly available
Your Collaborative Partner from Preclinical to Market Success
Accelerated Preclinical Development
Reliable Early-Phase Support
Efficient Late-Phase & Commercialization Solutions
Robust Commercial Services
Our Services
Drug Product Development
We provide cutting-edge formulation technologies tailored to optimize drug stability and efficacy in vials, syringes and cartridges. Our team tackles complex challenges, ensuring your biologic formulations are robust and market ready.
Analytical Services
Our state-of-the-art analytical methods offer comprehensive testing and validation under R&D and GMP to meet regulatory standards. From early development to release and stability testing, we provide critical insights to derisk your product’s journey to market.
Manufacturing Services
Our manufacturing services include GMP process development, manufacturing troubleshooting and high-quality, non-GMP therapeutic manufacturing services. We support the development of biologics and advanced therapy medicinal products (ATMPs), including gene and cell therapies, from preclinical development to commercial success.
Drug Product Development
We provide cutting-edge formulation technologies tailored to optimize drug stability and efficacy in vials, syringes and cartridges. Our team tackles complex challenges, ensuring your biologic formulations are robust and market ready.
Analytical Services
Our state-of-the-art analytical methods offer comprehensive testing and validation under R&D and GMP to meet regulatory standards. From early development to release and stability testing, we provide critical insights to derisk your product’s journey to market.
Manufacturing Services
Our manufacturing services include GMP process development, manufacturing troubleshooting and high-quality, non-GMP therapeutic manufacturing services. We support the development of biologics and advanced therapy medicinal products (ATMPs), including gene and cell therapies, from preclinical development to commercial success.
Coriolis by the Numbers
930
different modalities supported
17
years of experience
160
peer-reviewed articles authored
2700
projects performed successfully
800
global clients from preclinical to commercial projects
145
formulations developed
15
commercial products supported
Resources
Articles
Unlocking the Power of Analytical Ultracentrifugation (AUC) in Biopharmaceutical Development
June 18, 2025
